184 related articles for article (PubMed ID: 34548478)
1. Suppression of 4.1R enhances the potency of NKG2D-CAR T cells against pancreatic carcinoma via activating ERK signaling pathway.
Gao Y; Lin H; Guo D; Cheng S; Zhou Y; Zhang L; Yao J; Farooq MA; Ajmal I; Duan Y; He C; Tao L; Wu S; Liu M; Jiang W
Oncogenesis; 2021 Sep; 10(9):62. PubMed ID: 34548478
[TBL] [Abstract][Full Text] [Related]
2. Co-expression of IL-21-Enhanced NKG2D CAR-NK cell therapy for lung cancer.
Zhang Y; Zhang C; He M; Xing W; Hou R; Zhang H
BMC Cancer; 2024 Jan; 24(1):119. PubMed ID: 38263004
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity of NKG2D CAR-T cells against human colorectal cancer cells in vitro and in vivo.
Deng X; Gao F; Li N; Li Q; Zhou Y; Yang T; Cai Z; Du P; Chen F; Cai J
Am J Cancer Res; 2019; 9(5):945-958. PubMed ID: 31218103
[TBL] [Abstract][Full Text] [Related]
4. Manufacturing development and clinical production of NKG2D chimeric antigen receptor-expressing T cells for autologous adoptive cell therapy.
Murad JM; Baumeister SH; Werner L; Daley H; Trébéden-Negre H; Reder J; Sentman CL; Gilham D; Lehmann F; Snykers S; Sentman ML; Wade T; Schmucker A; Fanger MW; Dranoff G; Ritz J; Nikiforow S
Cytotherapy; 2018 Jul; 20(7):952-963. PubMed ID: 30180944
[TBL] [Abstract][Full Text] [Related]
5. DAP10 integration in CAR-T cells enhances the killing of heterogeneous tumors by harnessing endogenous NKG2D.
Li S; Zhao R; Zheng D; Qin L; Cui Y; Li Y; Jiang Z; Zhong M; Shi J; Li M; Wang X; Tang Z; Wu Q; Long Y; Hu D; Wang S; Yao Y; Liu S; Yang LH; Zhang Z; Tang Q; Liu P; Li Y; Li P
Mol Ther Oncolytics; 2022 Sep; 26():15-26. PubMed ID: 35784403
[TBL] [Abstract][Full Text] [Related]
6. T cells expressing NKG2D chimeric antigen receptors efficiently eliminate glioblastoma and cancer stem cells.
Yang D; Sun B; Dai H; Li W; Shi L; Zhang P; Li S; Zhao X
J Immunother Cancer; 2019 Jul; 7(1):171. PubMed ID: 31288857
[TBL] [Abstract][Full Text] [Related]
7. Development of NKG2D-based chimeric antigen receptor-T cells for gastric cancer treatment.
Tao K; He M; Tao F; Xu G; Ye M; Zheng Y; Li Y
Cancer Chemother Pharmacol; 2018 Nov; 82(5):815-827. PubMed ID: 30132099
[TBL] [Abstract][Full Text] [Related]
8. Memory T Cells Expressing an NKG2D-CAR Efficiently Target Osteosarcoma Cells.
Fernández L; Metais JY; Escudero A; Vela M; Valentín J; Vallcorba I; Leivas A; Torres J; Valeri A; Patiño-García A; Martínez J; Leung W; Pérez-Martínez A
Clin Cancer Res; 2017 Oct; 23(19):5824-5835. PubMed ID: 28659311
[No Abstract] [Full Text] [Related]
9. GMP-Compliant Manufacturing of NKG2D CAR Memory T Cells Using CliniMACS Prodigy.
Fernández L; Fernández A; Mirones I; Escudero A; Cardoso L; Vela M; Lanzarot D; de Paz R; Leivas A; Gallardo M; Marcos A; Romero AB; Martínez-López J; Pérez-Martínez A
Front Immunol; 2019; 10():2361. PubMed ID: 31649672
[TBL] [Abstract][Full Text] [Related]
10. Chimeric Antigen Receptor T Cells Targeting NKG2D-Ligands Show Robust Efficacy Against Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia.
Driouk L; Gicobi JK; Kamihara Y; Rutherford K; Dranoff G; Ritz J; Baumeister SHC
Front Immunol; 2020; 11():580328. PubMed ID: 33384686
[TBL] [Abstract][Full Text] [Related]
11. Lenalidomide improves NKG2D-based CAR-T cell activity against colorectal cancer cells invitro.
Zarei M; Abdoli S; Farazmandfar T; Shahbazi M
Heliyon; 2023 Oct; 9(10):e20460. PubMed ID: 37790973
[TBL] [Abstract][Full Text] [Related]
12. Eradication of Hepatocellular Carcinoma by NKG2D-Based CAR-T Cells.
Sun B; Yang D; Dai H; Liu X; Jia R; Cui X; Li W; Cai C; Xu J; Zhao X
Cancer Immunol Res; 2019 Nov; 7(11):1813-1823. PubMed ID: 31484657
[TBL] [Abstract][Full Text] [Related]
13. Co-Expression of IL-7 Improves NKG2D-Based CAR T Cell Therapy on Prostate Cancer by Enhancing the Expansion and Inhibiting the Apoptosis and Exhaustion.
He C; Zhou Y; Li Z; Farooq MA; Ajmal I; Zhang H; Zhang L; Tao L; Yao J; Du B; Liu M; Jiang W
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32698361
[TBL] [Abstract][Full Text] [Related]
14. DNAX-activating protein 10 co-stimulation enhances the anti-tumor efficacy of chimeric antigen receptor T cells.
Zhao R; Cheng L; Jiang Z; Wei X; Li B; Wu Q; Wang S; Lin S; Long Y; Zhang X; Wu Y; Du X; Pei D; Liu P; Li Y; Cui S; Yao Y; Li P
Oncoimmunology; 2019; 8(1):e1509173. PubMed ID: 30546945
[TBL] [Abstract][Full Text] [Related]
15. Control of triple-negative breast cancer using ex vivo self-enriched, costimulated NKG2D CAR T cells.
Han Y; Xie W; Song DG; Powell DJ
J Hematol Oncol; 2018 Jul; 11(1):92. PubMed ID: 29980239
[TBL] [Abstract][Full Text] [Related]
16. Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma.
Baumeister SH; Murad J; Werner L; Daley H; Trebeden-Negre H; Gicobi JK; Schmucker A; Reder J; Sentman CL; Gilham DE; Lehmann FF; Galinsky I; DiPietro H; Cummings K; Munshi NC; Stone RM; Neuberg DS; Soiffer R; Dranoff G; Ritz J; Nikiforow S
Cancer Immunol Res; 2019 Jan; 7(1):100-112. PubMed ID: 30396908
[TBL] [Abstract][Full Text] [Related]
17. Novel cellular immunotherapy using NKG2D CAR-T for the treatment of cervical cancer.
Zhang Y; Li X; Zhang J; Mao L
Biomed Pharmacother; 2020 Nov; 131():110562. PubMed ID: 32920508
[TBL] [Abstract][Full Text] [Related]
18. Structure-based rational design of a novel chimeric PD1-NKG2D receptor for natural killer cells.
Guo C; Wang X; Zhang H; Zhi L; Lv T; Li M; Lu C; Zhu W
Mol Immunol; 2019 Oct; 114():108-113. PubMed ID: 31351411
[TBL] [Abstract][Full Text] [Related]
19. Chimeric antigen receptor (CAR)-transduced natural killer cells in tumor immunotherapy.
Hu Y; Tian ZG; Zhang C
Acta Pharmacol Sin; 2018 Feb; 39(2):167-176. PubMed ID: 28880014
[TBL] [Abstract][Full Text] [Related]
20. Electroporation of NKG2D RNA CAR Improves Vγ9Vδ2 T Cell Responses against Human Solid Tumor Xenografts.
Ang WX; Ng YY; Xiao L; Chen C; Li Z; Chi Z; Tay JC; Tan WK; Zeng J; Toh HC; Wang S
Mol Ther Oncolytics; 2020 Jun; 17():421-430. PubMed ID: 32462079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
